Tag Archives: Option Care

NUZYRA Continues to be the Primary Driver for Paratek Pharmaceuticals’ Growth

The FDA approved Paratek’s supplemental New Drug Application (sNDA) for the oral-only dosing regimen of NUZYRA® for the treatment of adults with Community-Acquired Bacterial Pneumonia (CABP)

Duchenne Muscular Dystrophy (DMD) Patients Have Choice of Medications

The number of chronic infusion therapies for neuromuscular disorders continues to grow

Highmark Develops Initiatives to Control Drug Spending

Highmark members will receive hemophilia drugs exclusively from three specialty pharmacies